Plasma Cell Follow‑Up Flow Panel
Use
This flow cytometry panel is intended for follow‑up evaluation of plasma cell populations post‑treatment, providing only nine key markers (CD19, CD20, CD38, CD45, CD56, CD117, CD138, cytoplasmic kappa, cytoplasmic lambda) when full phenotyping is declined or unavailable. It is most appropriate when prior immunophenotyping has already been performed (e.g., NeoGenomics Standard or Extended Flow Panel), and clinical history or diagnostic reports are required to inform interpretation.
Special Instructions
Available in two levels of service: global (includes interpretation) and tech‑only. Ordering requires prior clinical history, including time post‑treatment, and preferably previous NeoGenomics flow or pathology reports. NY clients must provide date and time of collection. A CBC report must accompany bone marrow aspirate or peripheral blood specimens.
Limitations
This panel includes only nine markers and does not replace comprehensive immunophenotyping. Clients are strongly encouraged to perform full phenotyping with Standard or Extended Flow Panels for complete immunophenotypic characterization. Specimen viability is critical, and certain anticoagulants (lithium heparin, ACD) are not acceptable. Viability may be compromised if specimens are not received within specified timeframes (48–72 hours) or improperly stored.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Result Turnaround Time
24 hours
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
1‑2 mL EDTA
Minimum Volume
Not provided
Container
EDTA tube; sodium heparin acceptable; lithium heparin or ACD not acceptable
Collection Instructions
Provide recent CBC report
Storage Instructions
Refrigerate; do not freeze; use cold pack not in direct contact
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Receive within 72 hours (48 hours for NYS) |